Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study

医学 腹腔疾病 安慰剂 内科学 临床终点 胃肠病学 人口 不利影响 绒毛萎缩 面筋 临床试验 疾病 病理 环境卫生 替代医学
作者
Marja‐Leena Lähdeaho,Mika Scheinin,Pekka Vuotikka,Juha Taavela,Alina Popp,Johanna Laukkarinen,Jukka Koffert,Olli‐Pekka Koivurova,Marko Pesu,Laura Kivelä,Zsófia Lovró,Joni Keisala,Jorma J Isola,Jane R. Parnes,Francisco León,Markku Mäki
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:4 (12): 948-959 被引量:130
标识
DOI:10.1016/s2468-1253(19)30264-x
摘要

Background Interleukin 15 (IL-15) is implicated in the pathophysiology of coeliac disease. AMG 714 is the first anti-IL-15 monoclonal antibody to be investigated for the treatment of coeliac disease. We aimed to investigate the effects of AMG 714 in patients with coeliac disease who underwent gluten challenge. Methods This randomised, double-blind, placebo-controlled, parallel-group, phase 2a trial was done at three clinical sites in Finland. Inclusion criteria included age 18–80 years, a confirmed diagnosis of coeliac disease, and adherence to a gluten-free diet for at least 12 months before screening. Patients were randomly assigned (1:1:1) to 150 mg AMG 714, 300 mg AMG 714, or placebo using permuted blocks and stratified by study site and sex. Patients and study staff were masked to treatment assignment. Treatments were administered by two subcutaneous injections every 2 weeks for 10 weeks (total six doses). Patients without severe villous atrophy at baseline received a gluten challenge (2–4 g daily) during weeks 2–12. Small bowel biopsy samples were obtained for histological assessments at baseline and week 12. The primary efficacy endpoint was the percentage change from baseline to week 12 in villous height-to-crypt depth (VHCD) ratio. Secondary endpoints were CD3-positive intraepithelial lymphocyte density; clinical symptoms measured by gastrointestinal symptom rating scale (GSRS), coeliac disease GSRS, and Bristol stool form scale (BSFS); and changes in anti-tTG and anti-DGP antibodies from baseline. The primary analysis was done in the per-protocol 1 population of patients who received at least one dose of study drug and who underwent the gluten challenge. Safety analyses were done in all patients who received at least one dose of study drug. This trial is registered at ClinicalTrials.gov, NCT02637141 and EudraCT, 2015-003647-19. Findings Between April 13, 2016, and Nov 22, 2016, 64 patients were enrolled and randomly assigned to either the 150 mg AMG 714 group (n=22), the 300 mg AMG 714 group (n=22), or the placebo group (n=20). Two patients did not start treatment and two did not provide post-treatment biopsy samples. 49 patients underwent the gluten challenge (per-protocol 1 population) and 11 patients did not because of baseline villous atrophy. AMG 714 did not prevent mucosal injury due to gluten challenge. The least square mean difference in the relative change from baseline in VHCD ratio was −2·49% (95% CI −16·82 to 11·83; p=0·73) between 150 mg AMG 714 and placebo and 6·39% (−7·07 to 19·85; p=0·34) between 300 mg AMG 714 and placebo. Neither comparison was statistically significant. The density of CD3-positive intraepithelial lymphocytes increased in all groups, with smaller increases in the 300 mg group (−41·24% [95% CI −79·28 to −3·20] vs placebo, nominal p=0·03) but not the 150 mg group (−14·32% [–54·39 to 25·74], nominal p=0·47). Clinical symptoms were ameliorated with AMG 714 treatment between baseline and week 12, particularly diarrhoea as measured by the BSFS (nominal p=0·01 for 150 mg vs placebo, and nominal p=0·0002 for 300 mg vs placebo). Serum antibody titres for anti-tTG and anti-DGP antibodies increased in all three treatment groups, with no significant difference between AMG 714 and placebo. Treatment-emergent adverse events occurred in 21 (95%) patients in the 150 mg AMG 714 group, 0 (95%) in the 300 mg AMG 714 group, and 19 (100%) in the placebo group. The most common treatment-emergent adverse events were gastrointestinal disorders (17 [77%] participants in the 150 mg AMG 714 group, 16 [76%] in the 300 mg AMG 714 group, and 13 [68%] in the placebo group). Injection site reactions were the most common individual adverse event, reported in eight (36%) patients in the 150 mg AMG 714 group, 11 (52%) in the 300 mg group, and five (26%) in the placebo group. No serious adverse events occurred. Interpretation The primary endpoint, change in VHCD ratio from baseline after 12 weeks of treatment in patients with coeliac disease undergoing gluten challenge, was not significantly different between placebo and AMG 714 at either 150 mg or 300 mg. Effects on intraepithelial lymphocyte density and symptoms suggest that further research of AMG 714 may be warranted in patients with non-responsive coeliac disease. Funding Celimmune and Amgen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
u112完成签到,获得积分10
刚刚
番茄完成签到,获得积分10
刚刚
朴实归尘发布了新的文献求助10
1秒前
1秒前
烂漫映之完成签到 ,获得积分10
1秒前
Yoyo完成签到,获得积分10
2秒前
郭娅楠发布了新的文献求助10
2秒前
Ava的应助被tang采纳,获得10
2秒前
wyy发布了新的文献求助10
3秒前
3秒前
nana完成签到,获得积分10
4秒前
隐形曼青的应助被BBzc采纳,获得10
4秒前
4秒前
鹿立轩发布了新的文献求助10
5秒前
5秒前
Yoyo发布了新的文献求助10
5秒前
6秒前
LLJ完成签到,获得积分10
6秒前
6秒前
传奇3的应助被兵临城下采纳,获得10
7秒前
林xxxx发布了新的文献求助10
7秒前
吴军霄发布了新的文献求助10
7秒前
jj发布了新的文献求助10
9秒前
9秒前
健忘冰珍完成签到,获得积分10
10秒前
11秒前
12秒前
小高完成签到 ,获得积分10
12秒前
zhfliang发布了新的文献求助10
12秒前
Ava的应助被大大怪采纳,获得10
14秒前
然然发布了新的文献求助10
14秒前
14秒前
u110完成签到,获得积分10
15秒前
15秒前
吴军霄完成签到,获得积分10
15秒前
15秒前
15秒前
嘀嘀嘀发布了新的文献求助10
17秒前
壹肆伍完成签到,获得积分10
18秒前
健忘冰珍发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184240
求助须知:如何正确求助?哪些是违规求助? 9573297
关于积分的说明 21830585
捐赠科研通 7781300
什么是DOI,文献DOI怎么找? 3434285
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480814